Uncategorized
Neuraly Announces Strategic Sponsored Research Agreement with the University of Pennsylvania to Explore use of NLY01 to Therapeutically Target a Neuroinflammatory Mechanism of Glaucoma
GAITHERSBURG, Md.--(BUSINESS WIRE)--Neuraly, Inc, a clinical-stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced a strategic sponsored research agreement with the University of Pennsylvania to study the use of NLY01 to therapeutically target a neuroinflammatory mechanism of glaucoma. Qi N. Cui, M.D., Ph.D., an assistant professor of ophthalmology in the Perelman School of Medicine at the University of Pennsylvania, will serve as the p